Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > How much are ppl willing to sell if this goes to the moon??

<< Previous

Bullboard Posts

Next >>

Comment by indaknownewfieon Feb 27, 2021 5:26pm

327 Views

Post# 32679936

RE:RE:How much are ppl willing to sell if this goes to the moon??

Hey PT, nice to see some other longs still here still holding strong. Just like you., Love to see it go to a dollar brother, we'd both be rewarded but there may be a bigger potential upside. Like you, i will sell at different price points and play with the house's money. I have a lot of warrants in addition to a huge chunk of common shares. Patience may prove fruitful for both of us.

<< Previous

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables